Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report

Published:2016 Issue:11 Volume:39 Page:720-723
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Brzezniak Christina,Oronsky Bryan,Scicinski Jan,Caroen Scott,Cabrales Pedro,Dean Abrouk Nacer,Kim Michelle M.,Brown James F.,Reid Tony R.,Larson Christopher,Oronsky Arnold,Day Regina,Degesys Aiste,Carter Corey A.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitric Oxide in Hematological Cancers: Partner or Rival?;Antioxidants & Redox Signaling;2021-02-10

2. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001;Biorheology;2019-12-26

3. Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible;Future Medicinal Chemistry;2019-02

4. Cancer and Beyond: Discovery and Development of NO-Releasing Therapeutics;Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders;2019

5. The dichotomous role of H2S in cancer cell biology? Déjà vu all over again;Biochemical Pharmacology;2018-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP